To our knowledge, boron carrying pharmaceutical (BCP) exhibit low toxicity on normal cells in the BNCT implementation (Barth et al., 2012), our synthesized compounds were examined for their cytotoxicity effect using two different subtype of breast cancer cell line: MCF-7/HER2 (HER2 overexpression) and 4T1 (TNBC), meanwhile for the selectivity toward normal cells, we used 3T3 cells. The gene discussed is ERBB2; the disease is breast carcinoma.